The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia

Clin Pharmacol Ther. 2022 Feb;111(2):358-361. doi: 10.1002/cpt.2275. Epub 2021 May 16.

Authors

Mototsugu Tanaka¹, Mutsuhiro Ikuma¹, Wataru Asakura¹, Yasuhiro Fujiwara²

Affiliations

¹ Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
² Chief Executive, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

PMID: 33993499
DOI: 10.1002/cpt.2275

No abstract available

Publication types

Review

MeSH terms

Administration, Oral
Anemia / blood
Anemia / drug therapy*
Anemia / enzymology
Anemia / etiology
Biomarkers / blood
Hemoglobins / metabolism*
Humans
Japan
Prolyl-Hydroxylase Inhibitors / administration & dosage*
Prolyl-Hydroxylase Inhibitors / adverse effects
Renal Dialysis
Renal Insufficiency, Chronic / blood
Renal Insufficiency, Chronic / complications*
Renal Insufficiency, Chronic / therapy
Treatment Outcome

Substances

Biomarkers
Hemoglobins
Prolyl-Hydroxylase Inhibitors